Last reviewed · How we verify
Minodronate
At a glance
| Generic name | Minodronate |
|---|---|
| Also known as | Difumi |
| Sponsor | Peking University Third Hospital |
| Target | Geranylgeranyl pyrophosphate synthase, Farnesyl pyrophosphate synthase, Farnesyl diphosphate synthase |
| Modality | Small molecule |
| Therapeutic area | Bone |
| Phase | FDA-approved |
Approved indications
- Osteoporosis
Common side effects
Key clinical trials
- Efficacy and Safety of Minodronate in Patients With Low Back Pain (PHASE4)
- A Phase III Clinical Study of Minodronate Tablets in Postmenopausal Women With Osteoporosis (PHASE3)
- Clinical Results of Bisphosphonate and Denosumab Therapy Following Teriparatide Therapy for Japanese
- Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |